Mumbai: GlaxoSmithKline Pharmaceuticals Limited has announced the resignation of Upendra Singh, Commercial Head - General Medicines, effective from the close of business hours of 18th April 2025.

SEONGNAM, South Korea I April 7, 2025 I ABL Bio Inc. (KOSDAQ: 298380), a clinical-stage biotech company developing bispecific antibody technology for immuno-oncology and neurodegenerative diseases, ...

ABL Bio Inc., a South Korean biotech company, will license out its proprietary blood-brain barrier shuttle platform, called the Grabody-B, to UK-based pharmaceutical giant GSK plc in a deal expected ...

GSK has continued to flesh out its neuroscience strategy with a 2 billion pound sterling ($2.5 billion) deal to use a South Korean company’s tech to bypass the blood-brain barrier. ABL Bio has ...

ABL Bio Inc. announced April 7 that it sealed a potential £2.075 billion (US$2.65 billion) license deal with GSK plc, granting GSK global rights to use ABL’s blood-brain barrier (BBB) penetrating ...

GSK is paying to access ABL Bio’s Grabody-B platform, which potentially enables therapies to cross the blood-brain barrier. GSK is fronting £38.5 million (nearly $50 million), in a partnership with ...

Dr Jules Bayliss, a medical director at vaccine manufacturer CSL Seqirus, said the last time there were this many influenza cases early in the year was 2020 when Australia closed its international ...

CSL Seqirus in Melbourne's Parkville produces essential products for Australia, including antivenoms and the Q fever vaccine, while its Tullamarine facility, set to be operational in 2026 ...

Jules Bayliss, medical director for vaccines and biosecurity at CSL Seqirus, said Australia was seeing the highest numbers of influenza infections ever seen outside of the traditional flu season.

The NRT market is currently dominated by large, multibillion-dollar pharmaceutical companies, like Johnson & Johnson, which makes the Nicorette brand of products, the GlaxoSmithKline spinoff ...